Sherbrooke Park Advisers LLC Buys Shares of 5,325 Zoetis Inc. (NYSE:ZTS)

Sherbrooke Park Advisers LLC bought a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the fourth quarter, Holdings Channel reports. The fund bought 5,325 shares of the company’s stock, valued at approximately $868,000.

A number of other hedge funds have also made changes to their positions in ZTS. Atlantic Edge Private Wealth Management LLC raised its holdings in shares of Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 140 shares during the last quarter. Rakuten Securities Inc. raised its holdings in shares of Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 166 shares during the last quarter. Navigoe LLC acquired a new position in shares of Zoetis during the fourth quarter valued at approximately $30,000. Murphy & Mullick Capital Management Corp acquired a new stake in shares of Zoetis in the fourth quarter valued at approximately $44,000. Finally, Asset Planning Inc acquired a new stake in shares of Zoetis in the fourth quarter valued at approximately $58,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE ZTS opened at $160.26 on Friday. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The business’s 50 day moving average is $156.49 and its two-hundred day moving average is $165.56. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33. The stock has a market capitalization of $71.35 billion, a price-to-earnings ratio of 29.30, a PEG ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.22 billion for the quarter, compared to analysts’ expectations of $2.20 billion. During the same quarter in the prior year, the firm posted $1.38 EPS. The company’s revenue was up 1.4% compared to the same quarter last year. Research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on ZTS. Barclays increased their price target on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. UBS Group lowered their price target on Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, May 7th. Piper Sandler raised their price target on Zoetis from $205.00 to $210.00 and gave the stock an “overweight” rating in a research report on Monday. Stifel Nicolaus decreased their target price on Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a report on Monday, April 14th. Finally, StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $212.75.

Insiders Place Their Bets

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares of the company’s stock, valued at $1,868,244.30. This represents a 9.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares in the company, valued at $2,682,770. This trade represents a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.